The development of kidney organoids from induced pluripotent stem cells (iPSCs) is a significant advancement in personalized nephrology research. At Protheragen, we use advanced techniques of iPSC reprogramming and renal differentiation to create organoids that model specific diseases, particularly enabling the modeling of elusive genetic kidney disorders and expediting therapeutic discoveries.
Introduction to iPSC-Derived Kidney Organoids
The iPSC-derived kidney organoids are designed to create highly sophisticated microminiature tissues of the kidneys engineered from induced pluripotent stem cells (iPSCs) derived from patients to replicate the human kidney development, disease pathology, and medicine actions. Newer refinement steps such as changes in differentiation techniques like spatial transcriptomics guided modulation of cell fates, organ-on-a-chip platforms and vascularized co-culture systems, have significantly enhanced physiological functions like glomerular filtration and tubular secretion.
Fig.1 Generation of kidney organoids according to the protocol. (Long, H. Y., et al., 2024)
iPSC-Derived Kidney Organoids Development
In the past decade, researchers have improved protocols to direct the differentiation of iPSCs to renal lineages by mimicking the signaling pathways that control the morphogenesis of the kidney. With appropriate timing in the application of several small molecules and growth factors, it is now possible to produce organoids of kidneys that contain various segments of nephrons and populations of renal cells.
Generation of Complex Kidney Organoids:
Established differentiation procedures result in the iPSC derived organoids with a high degree of nephron complexity with podocytes, proximal and distal tubules, stromal cells, and even rudimentary components of the renin-angiotensin system. Recent improvements use patient specific iPSCs to model genetic kidney diseases, which allow for disease modifying insights, and CRISPR functional rescue experiments.
Optimization of Growth Factors:
The application of iPSC derived organoid culture TG1 with a modulation of FGF9, activin A, and WNT signaling pathways has substantially increased the maturation efficiency of organoids. Stage specific modulation of growth factor ratio at different stages of culturing greatly improves nephron patterning and functional polarization of the epithelial cells, while bioengineering efforts greatly enhance the vascular and tubular functionalities integration.
Table1. Novel approaches in iPSC-derived organoids induction. (Long, H. Y., et al., 2024)
| Novel approach |
Potential advantage/application |
Core differentiation protocol |
| Induced dorsal SPs from mouse ESCs and combined mouse ESC-derived NPs, UB and SPs to generate kidney organoid. |
Generated organoid showed improved UB branching and appropriate localization of NPs at the tips of UB, organoid structure resembled kidney in vivo. |
NP, UB and SP (up to day 6.5): Taguchi et al., 2014, 2017;
SP from day 6.5: new protocol |
| Developed 3D PSCs-derived induced UB organoid that mimics branching morphogenesis and develop into mature CD. |
Genetically modified UB organoids can model congenital anomalies of kidney and urinary tract. Provided enhanced understanding of development, regeneration, and diseases of the CD system. |
New protocol. |
| Replaced mouse NPCs with human iPSC-derived NPCs. |
Demonstrated the possibility to regenerate human kidneys from iPSC-derived NPCs. |
Taguchi et al., 2014, 2017 |
Our Services
Protheragen's focus is offering extensive services regarding the development of induced pluripotent stem cell derived kidney organoids to aid in research on rare kidney diseases. Our team guarantees accuracy and dependability throughout all phases of the development of induced pluripotent stem cell-derived kidney organoids by employing state of the art genetic engineering technologies and our vast knowledge in the field.
Workflow of iPSC-Derived Kidney Organoids Development
Maturation and Vascularization
iPSC-Derived Organoids Development for Various Rare Kidney Diseases
With its vast expertise, Protheragen offers an extensive range of kidney organoids services. Because of our extensive experience with kidney disease modeling, we can effortlessly tackle nearly all aspects of developing iPSC-derived kidney organoids, illuminating the field with fresh and personalized approaches to advance your scientific endeavors.
Why Choose Protheragen?
- Specialized Team: With vast knowledge in stem cell biology, tissue engineering, and kidney research, Protheragen's experts ensure that every project is well taken care of.
- Tailored Services: With the ability to customize the design and execution of a research project, Protheragen provides flexible solutions to address specific research requirements.
- Advanced Technology: Employing the use of the newest laboratories that have advanced 3D culture and organoid analysis technologies.
- Client Support: Protheragen builds jointed projects with clients, providing them with technical support and dialogues in project execution.
Protheragen is dedicated to offering comprehensive, one-stop preclinical development services, specializing in iPSC-derived kidney organoids development for rare kidney disease research. From diseases model development to drug safety evaluation, our services support every stage of your research process. If you are interested in our services, please don't hesitate to contact us.
References
- Khoshdel-Rad, N., A. Ahmadi, and R. Moghadasali. "Kidney Organoids: Current Knowledge and Future Directions." Cell Tissue Res 387.2 (2022): 207-24.
- Long, H. Y., et al. "Human Pluripotent Stem Cell-Derived Kidney Organoids: Current Progress and Challenges." World J Stem Cells 16.2 (2024): 114-25.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
